Doxorubicin entrapped in sterically stabilized liposomes: Effects on bacterial blood clearance capacity of the mononuclear phagocyte system

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 111-115

  Storm, Gert ^a   Ten Kate, Marian T ^b   Working, Peter K ^c   Bakker Woudenberg, Irma A J M ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MONONUCLEAR CELL; NONHUMAN; PHAGOCYTE; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BACTEREMIA; DOXORUBICIN; DRUG CARRIERS; FEMALE; LIPOSOMES; PHAGOCYTES; RATS;

EID: 0031930151     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gabizon, A., Goren D., and Barenholz, Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor cells. Isr. J. Med. Sci., 24: 512-517, 1988.
2. Gabizon, A. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am., 8: 431-450, 1994.
3. Allen, T. M., and Chonn, A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett., 233: 42-46, 1987.
4. Allen, T. M., Hansen, C., and Rutledge, J. Liposomes with prolonged circulation times: factors affecting uptake by the reticuloendothelial system. Biochim. Biophys. Acta, 981: 27-35, 1989.
5. Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: significant improvements in blood clearance, tissue disposition and therapeutic index of encapsulated drugs against implanted tumors. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
6. Woodle, M. C., Matthay, K. K., Newman, M. S., Hidayat, J. E., Collins, L. R., Redemann, C., Martin, F. J., and Papahadjopoulos, D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta, 1105: 192-200, 1992.
7. Huang, S. K., Lee, K. D., Hong, D., Friend, D. S., and Papahadjopoulos, D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res., 52: 5135-5143, 1992.
8. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
9. Gabizon, A. A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Delivery Rev., 16: 285-294, 1995.
10. Woodle, M. C., and Lasic, D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta, 1113: 171-199, 1992.
11. Storm, G., Belliot. S. O., Daemen, T., and Lasic, D. D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Delivery Rev., 17: 31-48, 1995.
12. Simpson, J. K., Miller, R. F., and Spittle, M. F. Liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Clin. Oncol., 5: 372-373, 1993.
13. James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., and Stewart, J. S. W. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol., 6: 294-296, 1994.
14. Bogner, J. R., Kronawitter, U., Rolinski, B., Truebenbach, K., and Goebel, F. D. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acquired Immune Defic. Syndr., 7: 463-468, 1994.
15. Gabizon, A., Isacson, R., Libson, E., Kaufman, B., Uziely, B., Catane, R., Ben-Dor, C. G., Rabello, E., Cass, Y., Peretz, T., Sulkes, A., Chisin, R., and Barenholz, Y. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol., 33: 779-786, 1994.
16. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., and Gabizon, A. Liposomal doxorubicin (DOX-SL): antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol., 13: 1777-1785, 1995.
17. Poste, G. Liposome targeting in vivo: problems and opportunities. Biol. Cell, 47: 19-37, 1983.
18. Allen, T. M., Murray, L., MacKeigan, S., and Shah, M. Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution. J. Pharmacol. Exp. Ther., 229: 267-275, 1984.
19. Storm, G., Oussoren, C., Peeters, P. A. M., and Barenholz, Y. Tolerability of liposomes in vivo. In: G. Gregoriadis (ed.), Liposome Technology, Ed. 2, Vol. 3, pp. 345-383. Boca Raton, FL: CRC Press, 1993.
20. Storm, G., Steerenberg, P. A., Van Borssum-Waalkes, M., and Crommelin, D. J. A. Effects of intraperitoneal administration of free and liposome-entrapped doxorubicin on rat peritoneal exudate cell populations. J. Drug Targeting, 4: 255-264, 1996.
21. Gabizon, A., Meshorer, A., and Barenholz, Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst., 77: 459-469, 1986.
22. Daemen, T., Hofstede, G., ten Kate, M. T., Bakker-Woudenberg, I. A. J. M., and Scherphof, G. L. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer, 61: 716-721, 1995.
23. Daemen, T., Regts, J., Meesters, M., ten Kate, M. T., Bakker-Woudenberg, I. A. J. M., and Scherphof, G. L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Controlled Release, 44: 1-9, 1997.
24. Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Stearne-Cullen, L. E. T., and Woodle, M. C. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis., 171: 938-947, 1995.
25. Working, P. K., Newman, M. S., Huang, S. K., Mayhew, E., Vaage, J., and Lasic, D. D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J. Liposome Res., 4: 667-687, 1994.
26. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1988.
27. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev., 9: 253-266, 1990.
28. Wu, N. Z., and Dewhirst, M. W. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc. Res., 46: 231-253, 1993.
29. Vaage, J., Mayhew, E., Lasic, D. D., and Martin, F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long-circulating liposomes. Int. J. Cancer, 51: 942-948, 1992.
30. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res., 52: 6774-6781, 1992.
31. Mayhew, E. G., Lasic, D., Babbar, S., and Martin, F. J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer. 51: 302-309, 1992.
32. Huang, S. K., Martin, F. J., Jay, G., Vogel, J., Papahadjopoulos, D., and Friend, D. S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol., 143: 10-14, 1993.
33. Vaage, J., Barbera-Guillem, E., Abra, R., Huang, A., and Working, P. K. Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer (Phila.), 73: 1478-1484, 1994.
34. Vaage, J., Donovan, D., Loftus, T., Uster, P., and Working, P. Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristin encapsulated in sterically stabilized liposomes. Eur. J. Cancer, 31A: 367-372, 1995.
35. Old, L. J., Clarke, D. A., Benacerraf, B., and Goldsmith, M. The reticuloendothelial system and the neoplastic process. Ann. NY Acad. Sci., 88: 264-280, 1960.
36. Levy, M. H., and Wheelock, E. F. The role of macrophages in defense against neoplastic disease. Adv. Cancer Res., 20: 131-163, 1974.
37. Qian, Q., Jutila, M. A., Van Rooijen, N., and Cutler, J. E. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol., 152: 5000-5008, 1994.
38. Roh, M. S., Kahky, M. P., Oyedeji, C., Klostergaard, J., Wang, L., Curley, S. A., and Lotzova, E. Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. Clin. Exp. Metastasis, 10: 317-327, 1992.
39. Stoychkov, J. N., Schultz, R. M., Chirigos, M. A., Paulidis, N. A., and Goldin, A. Effects of Adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res., 39: 3014-3017, 1979.
40. Haskill, J. S. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res., 41: 3852-3856, 1981.